12/13
07:50 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
12/11
05:04 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
12/11
06:29 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
12/8
06:06 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.
11/21
04:07 pm
phat
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
Low
Report
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
11/13
12:02 am
phat
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
Low
Report
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
11/4
08:00 am
phat
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Low
Report
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
11/3
07:59 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
10/31
10:07 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.
10/31
07:19 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/30
06:06 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Guggenheim.
10/30
07:00 am
phat
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
10/25
10:10 am
phat
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease [Yahoo! Finance]
10/25
09:59 am
phat
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Low
Report
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
10/23
08:00 am
phat
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
Low
Report
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
10/20
08:00 am
phat
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
Medium
Report
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
10/18
01:31 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at
Wall S
Medium
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at
Wall S
10/6
08:08 am
phat
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer [Yahoo! Finance]
Medium
Report
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer [Yahoo! Finance]
10/6
08:00 am
phat
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Medium
Report
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer